Your session is about to expire
← Back to Search
Monoclonal Antibodies
Ivonescimab for Squamous Cell Carcinoma
Phase 2
Waitlist Available
Led By Aung Naing, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Ability to understand and willingness to sign informed consent form prior to initiation of the study and any study procedures.
* Age ≥18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year.
Awards & highlights
Summary
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Eligible Conditions
- Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion; an average of 1 year.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and adverse events (AEs)
Trial Design
1Treatment groups
Experimental Treatment
Group I: IvonescimabExperimental Treatment1 Intervention
Participants found to be eligible to take part in this study, you will receive ivonescimab by vein over about 1-2 hours on Day 1 of each 21-day cycle (1 time every 3 weeks).
Find a Location
Who is running the clinical trial?
Summit TherapeuticsIndustry Sponsor
12 Previous Clinical Trials
2,721 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,030 Previous Clinical Trials
1,797,223 Total Patients Enrolled
Aung Naing, MDPrincipal InvestigatorM.D. Anderson Cancer Center
14 Previous Clinical Trials
1,753 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger